PKO Investment Management Joint Stock Co Increases Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• PKO Investment Management boosted its stake in Alnylam by 750% in Q4, buying an additional 6,000 shares to own 6,800 shares valued at about $2.704 million.
• Alnylam reported a strong Q1 beat—EPS of $1.99 vs. $0.90 expected and revenue of $1.17 billion—driven by Amvuttra sales that grew roughly 187% and helped lift revenue ~96% year‑over‑year.
• Analysts maintain a consensus "Moderate Buy" with a mean price target of about $471.96, while insiders sold ~38,656 shares in the last three months and institutional investors own ~92.97% of the stock.

PKO Investment Management Joint Stock Co boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 750.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,800 shares of the biopharmaceutical company's stock after buying an additional 6,000 shares during the period. PKO Investment Management Joint Stock Co's holdings in Alnylam Pharmaceuticals were worth $2,704,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Hussman Strategic Advisors Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $2,505,000. Benjamin Edwards Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 50.5% in the fourth quarter. Benjamin Edwards Inc. now owns 733 shares of the biopharmaceutical company's stock valued at $291,000 after purchasing an additional 246 shares during the period. Ashton Thomas Securities LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $274,000. PFA Pension Forsikringsaktieselskab acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $14,065,000. Finally, Horizon Investments LLC raised its stake in Alnylam Pharmaceuticals by 11.9% during the fourth quarter. Horizon Investments LLC now owns 451 shares of the biopharmaceutical company's stock worth $179,000 after purchasing an additional 48 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 beat driven by Amvuttra — Alnylam reported Q1 EPS of $1.99 and revenue of $1.17B, topping estimates; Amvuttra sales surged ~187% and helped drive 96% year‑over‑year revenue growth. Read More.
• Positive Sentiment: Brokerage support — Several brokerages continue to rate ALNY favorably (consensus around “moderate buy” and H.C. Wainwright remains a buy), which supports upside sentiment over the medium term. Read More.
• Neutral Sentiment: Mixed analyst target moves — Wells Fargo nudged its target slightly higher but kept an “equal weight” stance; RBC trimmed its target marginally but maintains an “outperform” view (still implying sizeable upside). These are tweaks rather than directional shifts. Read More. Read More.
• Neutral Sentiment: Investor materials and commentary available — Full earnings slide deck and call transcript were published (useful for modeling product-level trends and guidance; contributes to re‑rating discussions). Read More.
• Negative Sentiment: Risks and product headwinds — The quarter showed declines in collaborator revenue and Onpattro sales that offset some gains; an outside review highlighted a new regulatory risk and warned the stock could carry a higher risk of significant losses, which likely pressured sentiment. Read More.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,598 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $523,584.70. Following the sale, the executive vice president owned 36,606 shares of the company's stock, valued at $11,993,955.90. The trade was a 4.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Melissa Mclaughlin sold 2,286 shares of the company's stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the transaction, the insider owned 9,443 shares in the company, valued at $3,120,156.06. This trade represents a 19.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 38,656 shares of company stock worth $12,370,696 in the last three months. Company insiders own 0.86% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on ALNY. HC Wainwright reiterated a "buy" rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Bank of America restated a "buy" rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Chardan Capital reaffirmed a "buy" rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Canaccord Genuity Group upped their price objective on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a "buy" rating in a report on Tuesday, February 17th. Finally, Truist Financial cut their target price on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a "buy" rating for the company in a research note on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $471.96.

Alnylam Pharmaceuticals Trading Down 4.3%

Shares of ALNY stock opened at $296.11 on Friday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The firm has a market cap of $39.51 billion, a PE ratio of 80.90 and a beta of 0.31. The company has a 50-day moving average of $320.11 and a two-hundred day moving average of $376.83. Alnylam Pharmaceuticals, Inc. has a 1-year low of $245.96 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.90 by $1.09. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 118.63%. The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the firm earned ($0.44) EPS. The business's revenue was up 96.4% on a year-over-year basis. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.78 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.